News
-
-
-
COMMUNIQUÉ DE PRESSE
Informations privilégiées / Communiqué sur comptes, résultats
-
COMMUNIQUÉ DE PRESSE
Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
Sanofi's brivekimig shows positive results in phase 2a study for hidradenitis suppurativa, presenting clinically meaningful improvements in primary and secondary endpoints in biologic-naïve patients -
-
-
COMMUNIQUÉ DE PRESSE
Horus Pharma becomes additional commercialization partner for Formycon's Eylea® biosimilar FYB203 in selected European countries under the brand name Baiama®
Horus Pharma partners with Formycon for Eylea biosimilar commercialization in Europe under Baiama brand. Agreement includes upfront payments and royalties for Klinge. Aflibercept treats nAMD -
COMMUNIQUÉ DE PRESSE
A2Z Cust2Mate Solutions Corp. Announces Pricing of US$45 Million Upsized and Oversubscribed Public Offering of Common Shares
A2Z Cust2Mate Solutions Corp. announces pricing of upsized public offering led by institutional investors. Proceeds to fuel company's growth and expansion plans -
COMMUNIQUÉ DE PRESSE
BGSF, Inc. Announces Additional Information Regarding Pending Special Cash Dividend of $2.00 Per Share
BGSF, Inc. announces details on special cash dividend of $2.00 per share for shareholders, affecting trading on NYSE. Company offers property management solutions and resources -
